Abstract
Currently available non-invasive prenatal testing (NIPT) assays for fetal red cell and platelet antigens has shown clinical benefit in the management of at-risk pregnancies. However, the capacity for NIPT to predict the full range of antigens with clinically-significant maternal antibodies remains.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
